S. Pelissier

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial.

V. Servois, B. Asselain, F. Bidard, 2015, Cancer letters.

Abstract P2-02-17: T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

M. Espié, M. Bollet, G. Romieu, 2016 .

Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group.

R. de Crevoisier, C. Hennequin, D. Pasquier, 2022, Critical reviews in oncology/hematology.

Late toxicity and quality of life from GETUG-AFU 22 study.

L. Salomon, S. Guérif, P. Pommier, 2020 .

Anxiety and specific distress in women at intermediate and high risk of breast cancer before and after surveillance by magnetic resonance imaging and mammography versus standard mammography

J. Kop, A. Tardivon, A. Brédart, 2012, Psycho-oncology.

Perception of care and experience of examination in women at risk of breast cancer undergoing intensive surveillance by standard imaging with or without MRI.

J. Kop, A. Tardivon, A. Brédart, 2012, Patient education and counseling.

Abstract OT3-4-05: Use of early CIRculating tumor CElls count changes to guide the use of chemotherapy in advanced metastatic breast cancer patients: the CirCe01 randomized trial

B. Asselain, M. Campone, F. Bidard, 2012 .